Search results for "Chelation"

showing 6 items of 286 documents

Safety and Efficacy of Direct-Acting Antiviral Drugs in Patients with Haemoglobinophaties and Chronic Hepatitis C Infection

2016

Abstract Background and Aim: Direct-acting antiviral drugs (DAAs) have a very high efficacy in patients with hepatitis C virus (HCV) infection, but they have not been extensively used in patients with haemoglobinophaties. To evaluate the safety and efficacy of DAA regimens in this subset we used the ITHACA-SITE dataset, which includes patients with haemoglobinophaties and chronic HCV liver disease treated in Italy. Patients and methods: Between March 2015 and June 2016, 121 patients included in the ITHACA-SITE dataset started DAA regimens. Cirrhosis was defined by FibroScan®showing≥12 kPa performed within 6 months before the treatment. Regimen choice and use of ribavirin were based on viral…

medicine.medical_specialtyCirrhosisbusiness.industryRibavirinHepatitis C virusImmunologyCell BiologyHematologymedicine.diseasemedicine.disease_causeBiochemistryRegimenchemistry.chemical_compoundLiver diseasechemistryDiabetes mellitusInternal medicineImmunologymedicineChelation therapyAdverse effectbusinessBlood
researchProduct

Evidence for Three Distinct Classes of Phenotype Severity in Beta-Thalassaemia

2019

Background: Classification of phenotype severity in patients with beta-thalassaemia has so far relied mainly on expert opinion using parameters of genotype, clinical features at diagnosis, and transfusion requirement. The aim of this study was to use a large dataset of patients with beta-thalassaemia and evaluate a classification system based on onset variables agreed on by an international expert group, including age at diagnosis, at first transfusion, and at first iron chelation. Methods: A retrospective dataset of 7910 patients with homozygous or compound heterozygous beta-thalassaemia was used and subjected to cluster and classification analysis starting with the onset variables. Result…

medicine.medical_specialtyHeart diseasebusiness.industryCompound heterozygositymedicine.diseasePhenotypeIron chelationBeta-thalassaemiaInternal medicineHepatocellular carcinomaGenotypeMedicinebusinessProspective cohort studySSRN Electronic Journal
researchProduct

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative…

2010

Background Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has recently been made commercially available but its long-term efficacy on cardiac iron and function has not yet been established. Our study aimed to compare the effectiveness of deferasirox, deferiprone and desferrioxamine on myocardial and liver iron concentrations and bi-ventricular function in thalassemia major patients by means of quantitative magnetic resonance imaging. Design and Methods From the first 550 thalassemia subjects enrolled in the Myocardial Iron Overload in Thalassemia network, we retrospectively selected thalasse…

medicine.medical_specialtyLiver Iron ConcentrationthalassemiaThalassemiairon chelation therapycardiac magnetic resonance imagingGastroenterologythalassemia; iron chelation therapy; cardiac magnetic resonance imagingNOchemistry.chemical_compoundCardiac magnetic resonance imagingInternal medicinemedicinemedicine.diagnostic_testbusiness.industryDeferasiroxBeta thalassemiaMagnetic resonance imagingHematologymedicine.diseaseSurgeryDeferoxaminechemistrybusinessDeferipronemedicine.drug
researchProduct

Chelation treatment in sickle-cell-anaemia: much ado about nothing?

2011

Summary Blood transfusions may prevent and treat serious complications related to sickle-cell disease (SCD) when performed according to specific guidelines. However, blood transfusion requirements in SCD inevitably lead to increased body iron burden. An adequate chelation treatment may prevent complications and reduce morbidity and mortality. This review evaluates the effectiveness, safety and costs of chelation treatment. The included trials were examined according to the recommendations of the American College of Cardiology (ACC) and the American Heart Association (AHA). Overall, 14 trials and a total of 502 patients with SCD were included in this review. Deferoxamine alone (s.c. or i.v.)…

medicine.medical_specialtyPediatricsBlood transfusionDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentAnemia Sickle CellDiseaseIron Chelating Agentslaw.inventionBody ironchemistry.chemical_compoundRandomized controlled triallawmedicineHumansChelationIntensive care medicinebusiness.industryDeferasiroxHematologyChelation TherapyDeferoxamineTreatment OutcomechemistryCosts and Cost AnalysisDeferipronebusinessChelation treatment sickle-cell-diseasemedicine.drug
researchProduct

Iron Chelation Therapy in thalassaemia major: a sistematic review with meta-analyses of 1520 patients included on randomized clinical trials

2011

The effectiveness of deferoxamine (DFO), deferiprone (DFP), or deferasirox (DFX) in thalassemia major was assessed. Outcomes were reported as means±SD, mean differences with 95% CI, or standardized mean differences. Statistical heterogeneity was tested using χ2 (Q) and I2. Sources of bias and Grading of Recommendations Assessment, Development and Evaluation system (GRADE) were considered. Overall, 1520 patients were included. Only 7.4% of trials were free of bias. Overall measurements suggest low trial quality (GRADE). The meta-analysis suggests lower final liver iron concentrations during associated versus monotherapy treatment (p<0.0001), increases in serum ferritin levels during DFX 5, 1…

medicine.medical_specialtyPyridonesIronMEDLINEThalassemiaSiderophoresDeferoxamineIron Chelating AgentsChelation treatment thalassaemia clinical trials iron overload meta-analysisBenzoatesGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicinemedicineHumansVentricular FunctionDeferiproneMolecular BiologyRandomized Controlled Trials as TopicEjection fractionbusiness.industryMyocardiumbeta-ThalassemiaDeferasiroxBeta thalassemiaCell BiologyHematologyTriazolesmedicine.diseaseChelation TherapySurgeryDeferoxamineDeferasiroxTreatment OutcomeLiverchemistryMeta-analysisFerritinsMolecular MedicineDrug Therapy CombinationbusinessDeferipronemedicine.drug
researchProduct

Synthesis and characterization of Zwitterionic Zn(II) and Cu(II) coordination compounds with ring-substituted 2,2′-biimidazole derivatives

2016

Zwitterionic coordination compounds with strongly asymmetrical charge distribution were synthesized and characterized. Ring-substituted biimidazoles were used as the primary ligands for Zn and Cu compounds. Formation of Zwitterionic coordination compound was found to be strongly dependent on the pH of the reaction medium as well as on the ring and nitrogen substituents of the ligand. Reaction of the Df-R2biim (Df-R2biim = 2,2′-bi-1R-imidazole-5,5′-dicarboxaldehyde, R = Me, Et or Pr) with ZnCl2 in neutral conditions led to binuclear compounds [Zn2Cl4(Df-R2biim)2] with two bridging ligands (1a–c). Reaction with CuCl2·2H2O gave neutral mononuclear compound [CuCl2(Df-Me2biim)] (1d) with chelati…

sinkki (metallit)DenticityStereochemistrykupariProtonation010402 general chemistry01 natural sciencesMedicinal chemistryAldehydeCoordination complexInorganic Chemistrycrystal structureschemistry.chemical_compoundbiimidazoleMaterials ChemistryImidazoleChelationPhysical and Theoretical Chemistryta116chemistry.chemical_classificationzwitterionic compunds010405 organic chemistryLigandzincAcetal0104 chemical scienceschemistrycoppernon-coordinated compoundsInorganica Chimica Acta
researchProduct